关键词：CKD；肾小球滤；过率降低；尿白蛋白排泄；发生率高；EGFR测定排泄
摘 要：CKD is the continuous loss of kidney function characterized by reduced GFR, increased urinary albumin excretion, or both. The WHO identifies CKD as a major contributing factor to the incidences and outcomes of hypertension, diabetes, and CVD (three diseases targeted by the WHO). CKD is classified into five stages based on renal function and the level of urinary protein excreted as measured by an eGFR. The eGFR data are interpreted in relation to race, gender, age, and serum creatinine concentration.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Aranesp

04.1.2 Epogen/Procrit

04.1.3 Mircera

04.1.4 Renvela

04.1.5 Avapro

04.1.6 Bystolic

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Disease Overview

07.1 Etiology

07.2 Epidemiology

07.2.1 Mortality

07.2.2 Prevalence of CKD

08. Pipeline Analysis

08.1 Emerging Treatment Options

09. Market Landscape

09.1 Market Overview

09.2 Market Size and Forecast

09.3 Five Forces Analysis

10. Segmentation of Global CKD Market by

Route of Administration

10.1 Oral

10.2 SC

10.3 IV

11. Segmentation of Global CKD Market by

Mechanism of Action

11.1 ARBs

11.2 ACEIs

11.3 ESAs

11.4 PH Binders

11.5 Vasodilators

12. Geographical Segmentation

12.1 CKD Drugs Market in Americas

12.1.1 Market Size and Forecast

12.2 CKD Drugs Market in EMEA Region

12.2.1 Market Size and Forecast

12.3 CKD Drugs Market in APAC Region

12.3.1 Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2014

20.2.1 Competitive Assessment of Top Drugs Used for CKD

Treatment

20.2.2 Amgen

20.2.3 Actavis

20.2.4 Johnson & Johnson

20.2.5 F. Hoffmann-La Roche

20.2.6 Sanofi

20.3 Other Prominent Vendors

21. Key Vendor Analysis

21.1 Amgen

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Segmentation by Revenue 2013

Product 21.1.4 Portfolio by Revenue 2013

21.1.5 Business Segmentation by Revenue 2012 and 2013

21.1.6 Geographical Segmentation by Revenue 2013

21.1.7 Business Strategy

21.1.8 Recent Developments

21.1.9 SWOT Analysis

21.2 Actavis

21.2.1 Key Facts

21.2.2 Business Description

21.2.3 Business Segmentation

21.2.4 Business Segmentation by Revenue 2012 and 2013

21.2.5 Sales by Geography

21.2.6 Business Strategy

21.2.7 Key Information

21.2.8 SWOT Analysis

21.3 Johnson & Johnson

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation by Revenue 2013

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Geographical Segmentation by Revenue 2013

21.3.6 Business Strategy

21.3.7 Recent Developments

21.3.8 SWOT Analysis

21.4 F. Hoffmann-La Roche Ltd.

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Business Segmentation

Business Segmentation 21.4.4 by Revenue 2012 and 2013

21.4.5 Sales by Geography

21.4.6 Business Strategy

21.4.7 Key Information

21.4.8 SWOT Analysis

21.5 Sanofi SA

21.5.1 Key Facts

21.5.2 Business Description

21.5.3 Business Segmentation

21.5.4 Revenue by Business Segmentation

21.5.5 Revenue Comparison 2012 and 2013

21.5.6 Sales by Geography

21.5.7 Business Strategy

21.5.8 Key Developments

SWOT Analysis

22. Other Reports in this Series